Zuclopenthixol decanoate injection

- arteriosclerosis, a disease affecting the arteries
- convulsions, fits or seizures
- decreased blood supply to the brain
- diabetes, a disorder of metabolism in which the amount of sugar in the blood is too high
- feeling lethargic, indifferent, lost or remote
- glaucoma, a condition in which there is usually a build-up of pressure in the eye
- heart and blood vessel problems
- kidney problems
- liver problems
- low potassium and/or low magnesium levels in the blood
- organic brain syndrome
- parkinsonism, a disease of the brain affecting movement
- risk factors for stroke
- tardive dyskinesia, a reaction to some medicines with worm-like movements of the tongue, or other uncontrolled movements of the mouth, tongue, cheeks or jaw which may progress to the arms and legs.
- treatment for cancer
- if you or someone else in your family has a history of blood clots, as medicines like these have been associated with formation of blood clots 

Schedule H is a class of prescription drugs in India appearing as an appendix to the Drugs and Cosmetics Rules, 1945 introduced in 1945. These are drugs which cannot be purchased over the counter without the prescription of a qualified manufacture and sale of all drugs are covered under the Drugs and Cosmetics Act and Rules. It is revised at times based on the advice of the Drugs Technical Advisory Board , part of the Central Drugs Standard Control Organization [1] in the Ministry of Health and Family Welfare . The most recent schedule H (2006) lists 536 drugs from abacavir to zuclopenthixol . [2]

Zuclopenthixol, also known as Zuclopentixol or Zuclopenthixolum, is an antipsychotic agent. Zuclopenthixol is a thioxanthene-based neuroleptic with therapeutic actions similar to the phenothiazine antipsychotics. It is an antagonist at D1 and D2 dopamine receptors. Major brands of zuclopenthixol are Cisordinol, Acuphase, and Clopixol. This drug is a liquid. This compound belongs to the thioxanthenes. These are organic polycyclic compounds containing a thioxanthene moiety, which is an aromatic tricycle derived from xanthene by replacing the oxygen atom with a sulfur atom. Known drug targets of zuclopenthixol include 5-hydroxytryptamine receptor 2A, D(1B) dopamine receptor, D(2) dopamine receptor, D(1A) dopamine receptor, and alpha-1A adrenergic receptor. It is known that zuclopenthixol is metabolized by Cytochrome P450 2D6. Zuclopenthixol was approved for use in Canada in 2011, but is not approved for use in the United States.

Zuclopenthixol decanoate injection

zuclopenthixol decanoate injection

Media:

zuclopenthixol decanoate injectionzuclopenthixol decanoate injectionzuclopenthixol decanoate injectionzuclopenthixol decanoate injectionzuclopenthixol decanoate injection